IDWeek 2026: novel antifungal turletricin demonstrates positive Phase II results

The data presented at IDWeek is from the Phase II portion of the Platform Trial for Cryptococcal Meningitis (PLATFORM-CM). The data presented at IDWeek is from the Phase II portion of the Platform Trial for Cryptococcal Meningitis (PLATFORM-CM). Cryptococcal meningitis is a serious fungal infection caused primarily by Cryptococcus neoformans and Cryptococcus gattii. Credit: MMD Creative via Shutterstock.com. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation. With a free Clinical Trials Arena profile, you can: Experience unmatched clarity with a single platform that…

Source: Clinical Trials Arena